Barclays Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price

Amgen (NASDAQ:AMGN – Get Free Report) had its price objective increased by research analysts at Barclays from $400.00 to $430.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price would indicate a potential downside of 8.71% from the company’s previous close.

Several other analysts have also commented on AMGN. Freedom Broker lowered Amgen from a “buy” rating to a “hold” rating and raised their target price for the stock from $450.00 to $470.00 in a report on Friday, November 6th. Robert W. Baird lifted their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. BMO Capital Markets decreased their price target on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a report on Monday, October 12th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, October 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Amgen from $481.00 to $536.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $425.69.

Get Our Latest Analysis on AMGN

Amgen Stock Performance

NASDAQ:AMGN traded up $5.37 during mid-day trading on Monday, hitting $471.04. The company’s stock had a trading volume of 147,659 shares, compared to its average volume of 2,741,069. Amgen has a 1 year low of $312.39 and a 1 year high of $483.99. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The stock has a market cap of $254.79 billion, a price-to-earnings ratio of 27.38, a PEG ratio of 3.24 and a beta of 0.43. The business’s fifty day moving average is $425.31 and its two-hundred day moving average is $381.17.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business posted $5.64 EPS. Analysts anticipate that Amgen will post 23.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Amgen

Several institutional investors and hedge funds have recently modified their holdings of the business. CSM Advisors LLC boosted its position in Amgen by 74.7% during the third quarter. CSM Advisors LLC now owns 1,719 shares of the medical research company’s stock worth $725,000 after purchasing an additional 735 shares in the last quarter. Cetera Investment Advisers increased its position in shares of Amgen by 0.4% in the third quarter. Cetera Investment Advisers now owns 334,927 shares of the medical research company’s stock valued at $141,175,000 after buying an additional 1,383 shares in the last quarter. Empirical Finance LLC increased its position in shares of Amgen by 2.2% in the third quarter. Empirical Finance LLC now owns 19,284 shares of the medical research company’s stock valued at $8,128,000 after buying an additional 419 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Amgen during the 3rd quarter worth approximately $14,833,000. Finally, Perennial Investment Advisors LLC raised its stake in shares of Amgen by 20.5% during the 3rd quarter. Perennial Investment Advisors LLC now owns 3,731 shares of the medical research company’s stock worth $1,573,000 after buying an additional 635 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Recommended Stories

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.